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ABSTRACT
Statistical Methods for the Analysis of Mass Spectrometry-based Proteomics Data.
(May 2012)
Xuan Wang, B.S., University of Science and Technology of China, Anhui, China;
M.S., Texas A&M University
Chair of Advisory Committee: Dr. Alan R. Dabney
Proteomics serves an important role at the systems-level in understanding of
biological functioning. Mass spectrometry proteomics has become the tool of choice
for identifying and quantifying the proteome of an organism. In the most widely used
bottom-up approach to MS-based high-throughput quantitative proteomics, complex
mixtures of proteins are first subjected to enzymatic cleavage, the resulting peptide
products are separated based on chemical or physical properties and then analyzed
using a mass spectrometer. The three fundamental challenges in the analysis of
bottom-up MS-based proteomics are as follows: (i) Identifying the proteins that
are present in a sample, (ii) Aligning different samples on elution (retention) time,
mass, peak area (intensity) and etc, (iii) Quantifying the abundance levels of the
identified proteins after alignment. Each of these challenges requires knowledge of
the biological and technological context that give rise to the observed data, as well
as the application of sound statistical principles for estimation and inference. In this
dissertation, we present a set of statistical methods in bottom-up proteomics towards
protein identification, alignment and quantification.
We describe a fully Bayesian hierarchical modeling approach to peptide and pro-
tein identification on the basis of MS/MS fragmentation patterns in a unified frame-
work. Our major contribution is to allow for dependence among the list of top
candidate PSMs, which we accomplish with a Bayesian multiple component mixture
iv
model incorporating decoy search results and joint estimation of the accuracy of a list
of peptide identifications for each MS/MS fragmentation spectrum. We also propose
an objective criteria for the evaluation of the False Discovery Rate (FDR) associated
with a list of identifications at both peptide level, which results in more accurate
FDR estimates than existing methods like PeptideProphet.
Several alignment algorithms have been developed using different warping func-
tions. However, all the existing alignment approaches suffer from a useful metric
for scoring an alignment between two data sets and hence lack a quantitative score
for how good an alignment is. Our alignment approach uses “Anchor points” found
to align all the individual scan in the target sample and provides a framework to
quantitify the alignment, that is, assigning a p-value to a set of aligned LC-MS runs
to assess the correctness of alignment. After alignment using our algorithm, the p-
values from Wilcoxon signed-rank test on elution (retention) time, M/Z, peak area
successfully turn into non-significant values.
Quantitative mass spectrometry-based proteomics involves statistical inference
on protein abundance, based on the intensities of each protein’s associated spec-
tral peaks. However, typical mass spectrometry-based proteomics data sets have
substantial proportions of missing observations, due at least in part to censoring of
low intensities. This complicates intensity-based differential expression analysis. We
outline a statistical method for protein differential expression, based on a simple
Binomial likelihood. By modeling peak intensities as binary, in terms of “presence /
absence”, we enable the selection of proteins not typically amendable to quantitative
analysis; e.g., “one-state” proteins that are present in one condition but absent in
another. In addition, we present an analysis protocol that combines quantitative and
presence / absence analysis of a given data set in a principled way, resulting in a
single list of selected proteins with a single associated FDR.
vTo Jason Tang, Xincheng Tang, Shuhuan Wang and Hanming Wang
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NOMENCLATURE
AMT Accurate mass and time
ANOVA Analysis of variance
CDF Cumulative density function
FDR False discovery rate
GEV Generalized extreme value
LC-MS Liquid chromatographyCMass spectrometry
M/Z Mass over charge ratio
NET Normalized elution time
NMC Number of missed cleavage sites
NTE Number of tryptic ends
PEP Posterior error probability
PM Potential matches
PMF Probability mass function
PNNL Pacific northwest national laboratory
PSM Peptide spectrum match
RBF Radial basis function
RT Retention Time
SVM Support vector machines
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11. INTRODUCTION
1.1 General Background
Proteins Proteins are the the main component of physiological metabolic path-
ways of cells. Proteomics serves a important role in a systems-level understanding of
biological systems since it is the large-scale study of proteins, particularly their struc-
tures and functions. Mass spectrometry proteomics has become the tool of choice
for qualitative and quantitative study of the proteome of an organism. Fundamental
challenges in Mass spectrometry based proteomics include (i) Identification of the
peptide / proteins that are present in a sample, (ii) Aligning different samples on
Mass, elution time, intensity and etc. and (iii) Quantifying the abundance levels of
the identified proteins after alignment. We note that protein identification and quan-
titation are complementary exercises. Unidentified proteins cannot be quantified, and
the confidence with which a protein was identified should perhaps be incorporated
into that protein abundance estimate. All of these challenges require understanding
of the biological and technological perspective as well as the development of novel
statistical inference methodology.
The difficulty of protein level identification is generally caused by widespread
missingness, peptide degeneracy and misidentification. The limitation of existing
alignment algorithms include the lack of automated framework or quantitative sta-
tistical assessment. Large-scale missingness due in part to low abundance expression
contributes to the complexity of intensity-based protein quantitation. We describe
a fully Bayesian hierarchical modeling approach to peptide and protein identifica-
tion with False Discovery Rate constructed in a unified framework. Across different
experiment samples with identified peptide/protein, “Anchor Points” are defined and
This dissertation follows the style of IEEE Transactions on Very Large Scale Integration (VLSI)
Systems.
2used to align each identified peptide automatically and a p-value is assigned to a set
of aligned LC-MS runs to quantify the alignment performance. A statistical method
for protein differential expression is outlined on converted presence/absence data
based on a simple Binomial likelihood and a hybrid protocol is proposed to combines
quantitative and presence / absence analysis and result in a single list of selected
proteins with a single associated FDR.
1.2 LC-MS Proteomics
LC-MS refers to liquid-chromatography mass-spectrometry. Liquid chromatog-
raphy is a technique that could be used in protein differential expression studies by
separating peptides into multiple MS scans. This enables higher-resolution analysis
of the resulting mass spectra. Mass spectrometry is a tool for measuring mass-to-
charge ratios (M/Z) of ions.
The key components of a mass spectrometer are the ion source, mass analyzer,
and ion detector (Figure 1.1). The ion source is responsible for assigning charge to
each molecule. Mass analyzer measures the mass-to-charge(M/Z) ratio of each ion.
The detector captures the ions and measures the intensity of each ion species. In
terms of a mass spectrum, the mass analyzer is responsible for the m/z informa-
tion on the x-axis and the detector is responsible for the peak intensity information
on the y-axis. In recent years tremendous improvement in instrument performance
and computational tools are used. Several MS methods for interrogating the pro-
teome have been developed: Surface Enhanced Laser Desorption Ionization (SELDI)
[1], Matrix Assisted Laser Desorption Ionization (MALDI) [2] coupled with time-of-
flight (TOF) or other instruments, and gas chromatography MS (GC-MS) or liquid
chromatography MS (LC-MS). Since GC-MS and LC-MS allow for online separation
of complex samples and thus they are much more widely used in high-throughput
quantitative proteomics.
3Fig. 1.1. Mass spectrometry. The mass spectrometer consists of an
ion source, responsible for ionizing peptides, the mass analyzer and
the detector, responsible for recording m/z values and intensities,
respectively, for each ion species. Each MS scan results in a mass
spectrum, and a single sample may be subjected to thousands of
scans.
4Fig. 1.2. Sample preparation. Complex biological samples are first
processed to extract proteins. Proteins are typically fractionated to
eliminate high-abundance proteins or other proteins that are not of
interest. The remaining proteins are then digested into peptides,
which are commonly introduced to a liquid chromatography column
for separation. Upon eluting from the LC column, peptides are ion-
ized.
5Here we focus on the most widely-used bottom-up approach to quantitative MS-
based proteomics, LC-MS, which has become the tool of choice for identifying and
quantifying the proteome of an organism. A LC-MS-based proteomic experiment
requires several steps of sample preparation (Figure 1.2), including (i) cell lysis to
break cells apart and protein extraction, (ii) protein separation to spread out the
collection of protein into more homogenous groups, i.e. remove contaminants and
proteins that are not of interest, especially high abundance house-keeping proteins
that are not usually indicative of the disease being studied, (iii) protein digestion to
break intact proteins into more manageable peptide components. Once this is com-
plete, peptides are further separated into a more homogeneous mixture to be ionized
and introduced into the mass spectrometer. In tandem mass spectrometry (denoted
by MS/MS), several of the most intense (high abundance) peaks from a parent MS
(MS1) scan are automatically selected and the corresponding ions are subjected to
further fragmentation and scanning. This process is repeated until all candidate
peaks of a parent scan are exhausted [3], [4]. This results in a fragmentation pattern
for each selected peptide, providing detailed information on the chemical makeup of
the peptide.
MS/MS is preceded by LC separation and can more accurately be denoted by
LC-MS/MS. High-resolution LC-MS instruments (e.g., FTICR) are very fast and can
achieve mass measurements that are sufficiently accurate for identification purposes
by comparing the fragmentation patterns to fragmentation spectra in a database,
using software. Alignment on the scans is prerequisite for downstream quantita-
tive analysis since day-to-day and run-to-run variation in the complex experimental
equipment can create systematic biases. With identified peptide/protein informa-
tion as well as aligned elution time, m/z and peak intensity, it is possible to proceed
to the quantification of the abundance level of those proteins present. Each step
contributes to the overall variation in the estimation and inference of the MS based
proteomics.
61.3 Peptide/Protein Identification
To facilitate protein identification, proteins are usually separated, cleaved/digested
chemically or enzymatically into fragments. Digestion overcomes many of the chal-
lenges associated with the complex structural characteristics of proteins, as the re-
sulting peptide fragments are more tractable chemically, and their reduced size, com-
pared to proteins, makes them more amenable to MS analysis.
The first step in protein identification is the identification of the constituent pep-
tides. Multiple distinct peptides can have very similar or identical molecular masses
and thus produce a single intense peak in the initial MS (MS1) spectrum, making it
difficult to identify the overlapping peptides. The use of separation techniques not
only increases the overall dynamic range of measurements (i.e., the range of relative
peptide abundances) but also greatly reduces the cases of coincident peptide masses
simultaneously introduced into the mass spectrometer.
In tandem mass spectrometry (denoted by MS/MS), a parent ion possibly cor-
responding to a separated peptide is selected in MS1 for further fragmentation in
MS2. Resulting fragmentation spectra are compared to fragmentation spectra in a
database, using software like SEQUEST [5], Mascot [6] or X!Tandem [7], see Fig-
ure 1.3. PeptideProphet [8] is a widely-used for peptide identification by modeling
a collection of database match scores as a mixture of a correct-match distribution
and an incorrect-match distribution. The confidence of each match is assessed by its
estimated posterior probability of having come from the correct-match distribution,
conditional on its observed score. Improvements have been made to PeptideProphet
to avoid fixed coefficients in computation of discriminant search score and utilization
of only one top scoring peptide assignment per spectrum [9].
Protein identification can be carried out by rolling up peptide-level identification
confidence levels to the protein level, a process that is associated with a host of issues
and complexities [8]. The goal of the identification process is generally to identify
as many proteins as possible, while controlling the number of false identifications at
7Fig. 1.3. Peptide/protein identification. Peptide and protein identi-
fication is most commonly accomplished by matching observed spec-
tral measurements to theoretical or previously-observed measure-
ments in a database. In LC-MS/MS, measurements consist of frag-
mentation spectra, whereas mass and elution time alone are used in
high-resolution LC-MS. Once a best match is found, one of the fol-
lowing methods for assessing confidence in the match is employed:
decoy databases, empirical Bayes, or expectation values.
8a tolerable level. There are a myriad of options for the exact identification method
used, including (i) the choice of a statistic for scoring the similarity between an
observed spectral pattern and a database entry [7], [6], and (ii) the choice of how to
model the null distribution of the similarity metric [10], [11].
In each of the above approaches, there is a statistical problem of assessing confi-
dence in database matches. This is typically dealt with in one of two ways. The first
involves modeling a collection of database match scores as a mixture of a correct-
match distribution and an incorrect-match distribution. The confidence of each
match is assessed by its estimated posterior probability of having come from the
correct-match distribution, conditional on its observed score [12];
The second approach to assessing identification confidence involves the use of a
so-called “decoy database. A decoy database is created by scrambling the search
database so that any matches to the decoy database can be assumed to be false [13],
[12]. The distribution of decoy matches is then used as the null distribution for the
observed scores for matches to the search database, and p-values are computed as
simple proportions of decoy matches as strong or stronger than the observed matches
from the search database. A hybrid approach that combines mixture models with
decoy database search can also be used [13].
There are several limitations of current methods. First, many current methods
are designed to evaluate the top 1 ranked PSM returned by a database searching
application; this discard potential correct match that does not rank the first but
among the top several highest match score. Second, recent published work [14], [15],
[9] has extended the analysis from the top-ranked peptide per spectrum to a list of
candidate PSMs per spectrum with independent assumption which is against the un-
derlying truth that at most one PSM being correct. In Section 2, we describe a fully
Bayesian hierarchical modeling approach to peptide and protein identification on the
basis of MS/MS fragmentation patterns in a unified framework. Our major contri-
bution is to allow for dependence among the list of top candidate PSMs, which we
9accomplish with a Bayesian multiple component mixture model incorporating decoy
search results and joint estimation of the accuracy of a list of peptide identifications
for each MS/MS fragmentation spectrum. Peptide and protein network structure is
modeled in the latent stages of the hierarchical model. We also implement a novel
approach to the normalization of database searching scores to scores obtained from
decoy databases, which is demonstrated to greatly improve the peptide identification
performance. Finally, we propose an objective criteria for the evaluation of the FDR
associated with a list of identifications at both peptide level and protein level. Using
this criteria, our method is found to result in more accurate FDR estimates than
existing methods like Peptide Prophet [8].
1.4 Alignment
Peptides could also be identified on the basis of extremely accurate mass mea-
surements and LC elution times as the output of high-resolution LC-MS instruments.
When analyzing two independent samples, peptides elution times are affected by
shifts relative to instrumentation effects and it is common to observe systematic dif-
ferences in the elution times of similar samples on difference columns. However, the
LC-MS data have added dimension of m/z and intensity information, which makes
it not sufficient to provide alignment for individual peptides by only mapping the
retention time coordinates between two LC-MS samples. The goal of alignment is
then to match corresponding peptide features in terms of elution time, m/z and peak
intensity (see Figure 1.4) from different experiment samples so that the downstream
quantitation could be effectively employed.
A time warping method based on raw spectrum for alignment of LC-MS data was
introduced by Bylund and others [16], which is a modification of the original corre-
lated optimized warping algorithm [17]. Wang and others, implemented a dynamic
time warping algorithm allowing every Retention Time (RT) to be moved. Jaitly,
et al. [18] introduced a non-linear alignment technique that uses a dynamic time
10
Fig. 1.4. Two sample of scans before alignment, red dots represent
sample 1 and green dots represent sample 2. X axis is ScanNum
(equivalent to elution time), Y axis is M/Z and Z axis is Log (Peak
intensity).
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warping approach at a feature level. Radulovic and others [19] performed alignment
based on (m/z,RT) values of detected features by dividing the m/z domain into sev-
eral intervals and fitting different piece-wise linear time warping functions for each
m/z interval and then applying a “wobble” function to peaks and allow peaks to
move. Palmblad, et al. [20] applied a genetic algorithm to establish an alignment
warping function by using peptide elution times from MASCOT output to define
anchor points between two datasets.
All of these alignment techniques still suffer from either not taking m/z and peak
intensity information into account or manually inappropriate division of m/z domain
or incorrect parameterization of warping function as well as lacking a useful metric
for scoring an alignment between two datasets. To score alignments, a ground truth
is required to assess the accuracy of an alignment by establishing links between
datasets via database searches to find the same peptide present in two datastes.
(Simply matching two features based on mass and elution time alone is not very
supportive).
Our approach in Section 3 uses “Anchor points” found between two samples
to align all the individual scan in the second sample and provides a framework to
quantitify the alignment, that is, assigning a p-value to a set of aligned LC-MS runs
to assess correctness of alignment. In our method, for different experiments, we have
the elution time, mass over charge (m/z) value, peak intensities, peptide information
for each of the thousands of scans in the SEQUEST search output. A feature is
treated as an “anchor point” if it corresponds to very high confidence identification
to the same peptide in all samples (in addition to meeting other quality standards).
The anchors can be relied upon with very high confidence as being paired across
samples. As such, they can be used as the basis of an alignment algorithm, as well
as for assessing the performance of an alignment algorithm.
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Fig. 1.5. Overview of LC-MS-based proteomics. Proteins are ex-
tracted from biological sam- ples, then digested and ionized prior to
introduction to the mass spectrometer. Each MS scan results in a
mass spectrum, measuring m/z values and peak intensities. Based
on observed spectral information, database searching is typically em-
ployed to identify the pep- tides most likely responsible for high-
abundance peaks. Finally, peptide information is rolled up to the
protein level, and protein abundance is quantified using either peak
intensities or spectral counts
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Fig. 1.6. Protein quantitation. The left panel shows the proportion
of missing values in an example data set as a function of the mean of
the observed intensities for each pep- tide. There is a strong inverse
relationship between these, suggesting that many missing intensities
have been censored. The right panel shows an example protein found
to be differentially expressed in a two-class human study. The pro-
tein had 6 peptides that were identified, although two were filtered
out due to too many missing values (peptides 1 and 2, as indicated by
the vertical shaded lines). Estimated protein abundances and confi-
dence intervals are constructed from the peptide-level intensities by
a censored likelihood model [21].
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1.5 Protein Quantitation
Quantitative proteomics is concerned with quantifying and comparing protein
abundances in different conditions (Figure 1.5). Once a list has been constructed of
the proteins believed to be present in the sample and the peak intensity is aligned,
the next task is to quantify the abundance of the proteins. Protein abundance infor-
mation is contained in the set of peaks that correspond to the protein’s component
peptides. Peak height or area is a function of the number of ions detected for a par-
ticular peptide, and is related to peptide abundance [22]. Regardless of the specific
technology used to quantify peptide abundances, statistical models are required to
roll peptide level abundance estimates up to the protein level. Intensity based pro-
cedures for differential protein expression are naturally constructed in the context of
regression or ANOVA, or as a “rollup” problem [23].
However, intensity-based procedures are challenged by the presence of widespread
missing intensities, which are prevalent in MS-based proteomic data. In fact, it is
common to have 20% -40% of all attempted intensity measures missing. Abundance
measurements are missed if, for example, a peptide was identified in some samples
but not in others, see Figure 1.6. This can happen partially due to the low abun-
dances of present peptides, which is essentially a censoring mechanism [24]. With
standard regression or ANOVA procedures, peptides with missing values must either
be removed from the analysis, or their missing values must be imputed. There will
typically be very few peptides with no missing values, so filtering peptides in this
way results in a much less informative data set. The simple imputation routines
are not appropriate [25] since the vast majority of missing values are the results
of censoring of absent or low-abundance peptides. This complicates intensity-based
quantitation, as simple solutions will tend to be biased. For example, analysis of
only the observed intensities will tend to overestimate abundances and underesti-
mate variances. Simple imputation routines like row-means or k-nearest-neighbors
suffer from similar limitations. Parametric imputation and other specialized method-
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ology can be employed to enable intensity-based inference with lessened information
loss [21]. However, some information loss is inevitable. In particular, “one-state” (or
nearly so) peptides, those for which there are many observed intensities in one com-
parison group but few in another comparison group, are of great biological interest
but not amenable to an intensity-based analysis and filtered out in intensity-based
analysis. Statistical models are needed to address these issues, as well as to handle
the peptide-to-protein rollup [21], [26], see Figure 1.5.
In Section 4, we propose a “presence / absence” analysis, in which peak intensities
are digitized into binary measurements depending on whether a peak was observed
or not. Data collected in our laboratory does not necessarily have MS/MS frag-
mentation data associated with it, instead being obtained according to the Accurate
Mass and Time (AMT) tag pipeline [27]. We also present a hybrid analysis protocol
that consists of two stages: (i) intensity-based analysis, and (ii) a presence / absence
analysis. The results of each are merged to create a single collection of “interest-
ing” proteins, to which we use novel methodology to apply a single FDR. For the
proposed hybrid analysis protocol, we demonstrate the following: (i) Resulting FDR
estimates are conservative, (ii) One-state proteins are consistently selected as differ-
entially expressed, and (iii) The number of differentially expressed proteins selected
at a specified FDR exceeds that either intensity-based or presence / absence analysis
alone.
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2. A BAYESIAN HIERARCHICAL MODEL FOR PEPTIDE / PROTEIN
IDENTIFICATION BY LC-MS/MS.
2.1 Introduction
A fundamental challenge in quantitative mass spectrometry (MS)-based pro-
teomics is the identification of peptides and proteins that are present in a sample.
This is typically carried out by comparing observed features to entries in a database
of theoretical or previously-identified peptides (figure on page 7). In tandem mass
spectrometry (denoted by MS/MS or MSn), fragmentation spectra are obtained for
each subset of observed high-intensity peaks and compared to fragmentation spec-
tra in a database, using software like SEQUEST [5], Mascot [6], or X!Tandem [7].
Alternatively, high-resolution MS instruments can be used to obtain extremely ac-
curate mass and time (AMT) measurements, and these can be compared to AMT
measurements in a database [28]. In either case, a statistical assessment of the level
of confidence for each identification is desired; for the purposes of this section, we fo-
cus on peptide-spectrum matches (PSMs) and MS/MS. Protein identification can be
carried out by rolling up peptide-level identification confidence levels to the protein
level [8], or by the simultaneous modeling of peptides and proteins using hierarchical
models [29]. The goal of the identification process is generally to identify as many
features as possible, while controlling the number of false identifications at a toler-
able level. There are a myriad of options for the exact identification method used,
including (i) The choice of a statistic for scoring the similarity between an observed
spectral pattern and a database entry, and (ii) The choice of how to model the null
distribution of the similarity metric [10], [11].
There are several limitations of current methods. First, many current methods
are designed to evaluate the top 1 ranked PSM returned by a database searching
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application. Recent published work [14], [15], [9] have extended the analysis from
the top 1 ranked peptide per spectrum to a list of candidate PSMs per spectrum.
But existing approaches have made the assumption that multiple PSMs in the list of
candidate matches are independent. In complex samples, it is possible that multiple
peptides may give rise to very similar fragmentation patterns. However, it is reason-
able to expect that there is only one correct database entry that matches a specific
fragmentation pattern, in which case the PSMs in a list of top candidate matches
will not be independent. Our experiments suggest that the independence assump-
tion may lead to underestimated false discovery rates among identified peptides, see
figure on p. 36 in section 2.3.
In this section, we describe a fully Bayesian hierarchical modeling approach to
peptide and protein identification on the basis of MS/MS fragmentation patterns in a
unified framework. Our major contribution is to allow for dependence among the list
of top candidate PSMs, which we accomplish with a Bayesian multiple component
mixture model incorporating decoy search results and joint estimation of the accuracy
of a list of peptide identifications for each MS/MS fragmentation spectrum. Peptide
and protein network structure is modeled in the latent stages of the hierarchical
model. Our model can incorporate arbitrary collections of discriminant features for
quantifying match quality; examples include scores from different search applications
like XCorr and Sp from SEQUEST, hyperscore and E-value from X!tandem, and
other auxiliary discriminant information. We also implement a novel approach to
the normalization of database searching scores by utilizing scores obtained from
decoy databases, which is demonstrated to greatly reduce the dependency among
discriminant features, see figure on page 21. Finally, we propose an objective criteria
for the evaluation of the FDR associated with a list of identifications at peptide level.
Using this criteria, our method is found to result in more accurate FDR estimates
than existing methods like PeptideProphet [11].
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2.2 Methods
2.2.1 Experiments
The data we used came from 5 quality-control LC-MS/MS runs of Shewanella
oneidensis, prepared by and run at the Pacific Northwest National Laboratory. For
each sample, we have SEQUEST output for use in the peptide and protein identifi-
cation process.
2.2.2 Peptide and Protein Identification by Database Search
The identification of peptide assignments to MS/MS spectra is primarily based
on database search scores computed by different search engines together with var-
ious peptide-specific properties. Most database search approaches employ a score
function to measure the similarity between peptide MS/MS spectra and theoreti-
cal spectra constructed for each peptide in the searched protein sequence database.
Different search engines such as SEQUEST [5], X!tandem [7] and Mascot [6] adopt
different scoring systems. For example, SEQUEST computes a correlation score be-
tween a normalized MS/MS spectrum and a unit-intensity fragmentation model and
corrects it by an estimation of the background. X! Tandem defines a score function
based on the shared peak count approach and calculates an “expectation value” for
each peptide assignment. Mascot computes a probability-based score called the ion
score (often referred to simply as Mascot score) using the Mowse scoring algorithm.
Other than database search scores, some additional measurements might also contain
useful discrimination information, such as the difference (dT) between the observed
and predicted elution time (such as the “Normalized Elution Time” (NET) [30]),
the difference between the measured and calculated peptide mass (dM), the frac-
tional difference between current and second best Xcorr δCn , the Number of Tryptic
Ends (NTE), the Number of Missed Cleavage Sites (NMC), the peptide degeneracy
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measurement “multi-protein”. All these features are potentially informative for dis-
tinguishing between correct and incorrect PSMs. Ideally, incorporating all available
discriminant features should greatly improve tandem mass spectrum identification.
In this section, we consider a target-decoy search strategy, which has been used
successfully in peptide and protein identification analysis [10]. Decoy databases are
usually created by reversing or randomly shuffling the target peptide sequences. The
distributions of some PSM attributes (e.g., peptide length, elution time, charge state,
database search score) from a decoy database search are assumed to be the same as
those of false identifications from target database search. And incorrect PSMs from
decoy sequences are assumed to be equally as likely as those from target sequences.
Based on these assumptions, target-decoy search strategies have been successfully
used to distinguish correct identifications from incorrect ones [14], [31] and estimate
confidence levels for peptide assignments [32].
In some cases, database search scores should be transformed prior to analysis.
For example, consider the SEQUEST primary score, XCorr, a measure of the cor-
relation between observed and theoretical fragmentation spectra. XCorr is highly
dependent on peptide length and precursor ion charge state (see, e.g., [11] and [33]).
In particular, long peptides tend to have higher XCorr values than short peptides,
due simply to more frequent random matching of observed and theoretical spectral
features. Precursor ions with different charge states also have different probabili-
ties of having random hits, yielding shifts in the distributions of XCorr scores. To
alleviate this problem, PeptideProphet normalizes XCorr based on a deterministic
transformation, which is a function of peptide length. The transformed XCorr is
denoted as XCorr′. Due to the existence of charge state effects in the transformed
XCorr, PeptideProphet models each charge state separately.
We propose a novel approach to the normalization of discriminant scores, utilizing
the scores observed for matching to the decoy database. As an example, assuming
the top R ranked decoy XCorr scores for each spectrum are available, we normal-
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ize the target XCorr scores by subtracting the average XCorr scores for the top R
ranked decoy PSMs. In what follows, we let XCorr∗ denote the decoy-normalized
version of XCorr. The underlying assumption of this transformation is that peptide
length dependence and charge state dependence in decoy XCorr scores can be used
to approximate the corresponding dependencies in target XCorr scores.
This transformation is easy to implement yet effective to reduce the sequence
length dependence and charge state dependence. Figure 2.1 clearly suggests that
the distribution of the normalized XCorr score shows much weaker dependence on
peptide length and charge state. In addition, XCorr∗ is by nature a measurement of
relative XCorr score defined for the top R ranked target PSMs. XCorr∗ alone offers
comparable discrimination information with both XCorr
′
and δCn . Because of these
desired properties, we employ XCorr∗ as a primary SEQUEST searching score in the
subsequent analysis.
When multiple (transformed) discriminant features are available, one common
strategy is to combine (a subset of) them into a single discriminant score for simplifi-
cation purposes, which can greatly relieve the complexity of the subsequent mixture
distribution specification. There are many dimension reduction and classification
tools to choose from, including linear discriminant analysis (LDA), principle com-
ponent analysis (PCA), logistic regression and support vector machines (SVM). For
example, PeptideProphet employs LDA to derive a scaler score “fval” from a num-
ber of database search scores. All other information together with “fval” is modeled
in an unsupervised or semi-supervised fashion at subsequent steps [11], [31], [13].
Percolator uses a semi-supervised machine learning method that iteratively trains a
SVM classifier containing all discriminant features [14], where each PSM is assigned
a decision score.
In this section, we employ a similar approach as Percolator, using a radial basis
function (RBF) as the kernel function to train a semi-supervised SVM in a dynamic
fashion. The top 1 ranked target and all decoy discriminant features are used as
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Fig. 2.1. Scatter plot of normalized Xcorr vs peptide length and
charge state. The top left panel (green) is the scatter plot of Xcorr
vs Peptide length before normalization and reveals a positive corre-
lation by the fitted lowess curve. The top right panel (red) is the
scatter plot of Xcorr vs Peptide length after normalization. The
lowess curve fitted is essentially flat, indicating a much weaker de-
pendency on peptide length. The bottom left panel (green) is the
scatter plot of Xcorr vs charge state before normalization and re-
veals a positive correlation by the fitted lowess curve. The bottom
right panel (red) is the scatter plot of Xcorr vs charge state after
normalization with the fitted lowess curve relatively flat, indicating
a much weaker dependency on charge state after normalization.
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the training dataset, and the combined discriminant score is then calculated for all
of the top R target PSMs using the SVM function derived by the training dataset.
Figure 2.2 shows the distributions of target and decoy SVM scores. The bi-modality
of the distribution of target scores clearly suggests that target PSMs are comprised
of a mixture of correct and incorrect PSMs, suggesting the use of mixture modeling.
Also, the distribution of scores assigned to decoy PSMs is very similar to the distri-
bution for incorrect target scores. We note that SVM is primarily used as for scoring
purposes, rather than as an ultimate classifier or validation tool in the identification
process. There are many other scoring approaches for classification tools that might
achieve better combined discriminant scores. It is also possible to apply SVM to
database search scores only and then specify a multivariate mixture distribution for
the database search score combined with other discriminant information. However,
it is beyond the scope of this section to discuss and compare all of these possibilities.
2.2.3 Model
Many existing approaches to peptide identification are designed to model the top
1 scoring PSM for each spectrum only (ranked according to a certain scoring cri-
terion). The combined discriminant score (or multiple discriminant scores) can be
modeled as a parametric or semi-parametric mixture distribution with two compo-
nents representing correct and incorrect identifications, respectively. In a Bayesian
framework, the posterior probability that a PSM belongs to the correct-match dis-
tribution can be used as a statistical measure of confidence.
In this section, we present a model that accommodates a list of potential matches
(PM) for each spectrum. We might, for instance, wish to use the top 10 ranked PSMs
returned by a particular searching application, or a list of unique top 1 ranked PSMs
based on multiple search algorithms. In practice, it is expected that many correct
peptide assignments are ranked slightly lower than the top 1 ranked PSM based on
an algorithm-derived score. Our goal is to take advantage of the information for all
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Fig. 2.2. SVM scores. The histograms and density curves of target
and decoy SVM scores. The left panel with green curves is the distri-
bution of the decoy SVM score and the right panel with red curves is
the distribution of the target SVM score. The decoy histogram and
density curve have similar shape to the incorrect SVM score in target
PSMs.
24
available discriminant features and peptide protein grouping information to bump
correct PSMs up the ranking list. This would enable us to discover more correct
PSMs than approaches based on single best PSM scores alone.
In this approach, database search algorithms such as SEQUEST are employed
to filter out a list of candidate PSMs and calculate their corresponding discriminant
features. The subsequent statistical analysis serves as a second search step to find
the most likely match within the candidate list based on their estimated confidence
levels. Although several existing approaches also consider multiple peptide assign-
ments per spectrum [14] and [15], they typically impose independence assumption
in the correctness for PSMs in the same candidate list. However, this assumption
may not hold in practice and could render higher false discovery rate. For example,
given that one candidate PSM has a significantly higher chance to be correct, the
probability that other candidates are also correct should be low.
We relax the independence assumption in our approach. A multiple component
mixture model is proposed in the first stage to jointly infer the correctness of every
candidate PSM for each spectrum based on the combined discriminant score. Since
the prior probabilities of being correct matches are connected to the unobserved pres-
ence/absence of peptides and proteins. We employ a Bayesian hierarchical modeling
approach that models peptide and protein network information in the latent layers.
Some common complexities in peptide/protein identifications are also addressed in
our model.
The First Stage: a Multi-component Mixture Model for Discriminant Scores
We introduce some notations first. Assume we have K experimental spectra, each
of which is assigned a PM list with Rk PSMs, e.g., the top R ranked PSMs from
SEQUEST. Let srk denote the combined discriminant score of the rth match for spec-
trum k, r = 1, · · · , Rk, k = 1, ..., K. Let sk,1:Rk = (sk,1, sk,2, ..., sk,Rk) denote a vector
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containing scores for those R matches, s1:Rk\r = (sk,1, sk,2, ..., sr−1, sr+1, ..., sk,Rk),
denote a vector containing scores for all candidates except for the rth match.
We introduce a Rk + 1 dimensional component label vector Zk, where the rth
element of Zk, Zk,r = (Zk)r, is a binary indicator. We assume there is at most
one correct PSM in the PM list for each spectrum. Zk,Rk+1 = 1 indicates none
of the Rk matches in the PM list being correct. For r from 1 to Rk, Zk,r = 1
indicates the rth PSM is the only correct match in the PM list for spectrum k.
Define pk = (pk,1, ...., pk,Rk+1)
′
, where pk,r = Pr(Zk,r = 1). Then
∑Rk+1
r=1 pk,r =
1. The imposition of this restriction connects the probabilities of being correct for
multiple PSMs assigned to the same spectrum. It enables us to compute the peptide
probabilities for one candidates while taking into account information from other
matches in the same PM list.
Let f1 denote the density function for score with correct-match and f0 denote
the density function for score with incorrect-match. Conditional on the label vector
Zk, discriminant scores are assumed to be independently following the distribution
shown below,
Pr(sk|Zk) =
Rk∏
r=1
f1(sk,r)
I(Zk,r=1)f0(sk,r)
I(Zk,r=0)
Integrating out the latent label vector Z, it yields a mixture distribution with Rk +1
components for target discriminant scores.
s
(target)
k,1:Rk
∼
Rk∑
r=1
I(Zk,r = 1)f1(s
(target)
k,r )f0(s
(target)
k,{1:Rk}\r) + I(Zk,Rk+1 = 1)f0(s
(target)
k,1:Rk
)
∼
Rk∑
r=1
pk,rf1(s
(target)
k,r )f0(s
(target)
k,1:Rk\r) + pk,0f0(s
(target)
k,{1:Rk})
Recall that distribution of decoy scores provides a satisfying approximation to
the distribution of scores from incorrect target matches. Incorporating decoy scores
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in the model could obtain improved robustness in the estimation of f0 and hence
better discrimination for target PSMs. The model is:
sk,1:R
(incorrect) ∼ f0(s(decoy)k,1:R ) (2.1)
The choice of functional forms for f0 and f1 will depend on the specific method
used to derive the combined database search score. In our case, we used Xcorr,
Rank Sp, NTE, “multi-protein” and charge state as the covariates for the combined
SVM score, which greatly simplifies the task of mixture distribution specification.
We model f0 using the generalized extreme value (GEV) distribution with location
parameter µ0, scale parameter σ0 and shape parameter ξ0. The GEV distribution is
the limit distribution of properly normalized maxima of a sequence of independent
and identically distributed random variables. It is commonly used as an approxima-
tion to model the maxima of long (finite) sequences of random variables. In our case,
the combined scores for PSMs in the PM list are among the highest of the entire
database, making GEV distribution a natural choice for f0. The diagnostic analysis
also showed that the GEV distribution can describe the shape of combined discrimi-
nant score well, see Figure 2.3. Similarly, empirical exploration study suggests using
a GEV density to model f1 rather than a normal density, with location paramter µ1,
scale parameter σ1 and shape parameter σ0 to be estimated, see Figure 2.4.
Latent Stages: Prior Models for Peptide and Protein Network
In tandem MS/MS dataset, peptide level and protein level information are nat-
urally connected in a hierarchical structure. Figure on page 29 briefly illustrates
the work flow of the LC-MS/MS experiment and the peptide and protein network
information. As is shown in this figure, each protein can generate a list of peptides
and some peptides can be generated by multiple proteins. If peptide j is correctly
identified and unique to protein i, then protein i must be present in the sample,
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Fig. 2.3. Diagnostic of GEV fit on f0, the density of incorrect match-
ing scores. Left panel is quantile plot, the blue line is diagonal line.
Right panel is density curve vs histogram.
28
Fig. 2.4. Diagnostic of GEV fit on f1, the density of correct match-
ing scores. Upper Left panel is GEV quantile plot, the blue line is
diagonal line. Upper right panel is Normal quantile plot, the blue
line is fitted QQ-line. Bottom left panel is GEV density curve vs his-
togram and bottom right panel is normal density curve vs histogram
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which in turn implies higher chance of detecting the sibling peptides of peptide j in
the experiment.
Many conventional approaches follow a two step procedure to assess peptide and
protein confidence levels, in which peptide confidence levels are obtained from a like-
lihood model for discriminant score(s) in the first step and protein confidence levels
are estimated based on the peptide-level results. Apparently, by borrowing strength
from peptide/protein grouping information, an integrated analysis can produce more
accurate assessment for peptide and protein identification [29].
There are two major complexities that need to be addressed in modeling peptide
and protein network. The first complexity is called “degeneracy” problem [11]. If a
peptide can be generated by multiple proteins, then it adds ambiguity into protein
identification since we only know at least one of these proteins must be present. Few
work has been done to address this problem. Another common complexity is that
multiple spectra with different scores can be assigned to the same peptide, again,
adding ambiguity in assessing confidence levels for peptides with multiple spectra.
This complexity primarily arise from two different situations: i) tandem MS/MS
technique can generate repeated fragment ion spectra [34], which are mostly likely
to be assigned to the same peptide; ii) a false identified peptide can be assigned to
multiple spectra due to random matches. Many conventional approaches only keep
the maximum score for analysis, leading to two potential limits. First, it ignores
information from other spectra that may help with peptide identification. For exam-
ple, if multiple PSMs associated with the same peptide are due to repeated spectra,
larger number of repeated spectra should imply higher peptide confidence level. Sec-
ond, if multiple PSMs associated with the same peptide are due to random matches,
ignoring information from lower scores can possibly yield overestimated peptide con-
fidence level since a false identified peptide can be assigned with a high score by
chance. Apparently, modeling multiple PSMs to the same peptide would require
distinguishing those two situations. Frank etal. [34] propose a clustering approach
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Fig. 2.5. Simplified outline of the experimental steps and work flow
of the data in a typical high-throughput MS-based analysis of com-
plex protein mixtures. Each sample protein (open circle) is cleaved
into smaller peptides (open squares), which can be unique to that
protein or shared with other sample proteins (indicated by dashed
arrows). Peptides are then ionized and selected ions fragmented to
produce MS/MS spectra. Some peptides are selected for fragmen-
tation multiple times (dotted arrows) while some are not selected
even once. Each acquired MS/MS spectrum is searched against a
sequence database and assigned a best matching peptide, which may
be correct (open square) or incorrect (black square). Database search
results are then manually or statistically validated. The list of identi-
fied peptides is used to infer which proteins are present in the original
sample (open circles) and which are false identifications (black cir-
cles) corresponding to incorrect peptide assignments. The process of
inferring protein identities is complicated by the presence of degener-
ate peptides corresponding to more than a single entry in the protein
sequence database (dashed arrows) [8]
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to identify redundant spectra and replace each cluster with a single representative
spectrum. We believe this clustering type of approaches followed by database search
applications can greatly reduce the number of repeated spectra. However, it may
not be able to find all redundant spectra.
Bayesian hierarchical model is a convenient choice that allows us to incorporate
different levels of information in a unified framework. We describe models with
multiple latent layers to describe peptide and protein network. Models at latent
stage is connected to the mixture model in the first stage through the prior model
for pZ|Y . In this section, we describe a model based approach to address the two
major complexities discussed above.
We first introduce peptide level indicator and protein level indicator. Let Xi
denote a binary indicator such that Xi = 1 if protein i is present in the sample
and detected, and 0 otherwise. Let Yj be a binary indicator such that Yj = 1 if
peptide j is present in the digested sample and detected, and 0 otherwise. Let
pep(k, r) denote the peptide index number of the rth PSM for spectrum k. Recall
Z is a Rk + 1 dimensional component label vector Zk, where the rth element of Zk
indicating whether the rth match is correct for r ≤ Rk. Conditional on peptide
indicator Y , PSM indicators Z and protein indicators X are independent. Based on
peptide and protein network information, we build three models in the latent stages,
Pr(Z|Y ), Pr(Y |X) and Pr(X) respectively.
The Second Stage: Pr(Z|Y)
Conditional on a peptide is absent, it is reasonable to assume that all PSMs
that are matched to this peptide are incorrect. If a peptide is correctly detected
and only one PSM is matched to it, we assume that PSM is correct. If a peptide
is correctly detected but have multiple hits, it is possible that some hits are due to
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random matching. Those assumptions become the major guideline for us to model
the conditional probability, Pr(Z|Y ).
Pr(Z|Y ) = Pr(Zk,r = 1|Ypep(k,r)) =
τk,r Ypep(k,r)=1
0 Ypep(k,r)=0
(2.2)
where τk,r is the conditional probability that the rth match for spectrum k is correct
given peptide pep(k, r) is present. As we discussed above, if multiple PSMs assigned
to the same peptide originate from repeated spectra, we expect their conditional
probabilities of being correct are consistently close to 1. If PSMs are assigned to
the same peptide by random chance, we expect their conditional probabilities of
being correct take a much smaller value than 1. We use DM , the difference between
observed Mass and theoretical Mass as a major covariate to distinguish between
repeated spectra and random matches. When a PSM is unique to a peptide, DM = 0.
We expect its conditional probability to be 1 or close to 1. In other cases, we expect
that the larger the absolute deviation is, the more likely the PSM is assigned due
to random matching. A logistic regression or Probit model using DM as covariate
information is desired to model the conditional probability τk,r. For simplicity, we
pick a threshold C for DMk,r and assume a prior model for τk,r as follows:
τk,r =
1 |DMk,r| ≤ C
τ |DMk,r| > C
(2.3)
Based on exploratory data analysis on previously observed NET combined with
expertise’s suggestion, we choose C = 0.5 as a threshold. τ is an unknown parame-
ter. We assign a prior distribution on this parameter and estimate it using MCMC
approach (see Appendix for details).
The Third Stage: Pr(Y|X)
If a protein is absent, it is reasonable to assume that none of its constituent
peptides can be correctly detected. If a protein is present, it is common that only
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a subset of its constituent peptides can be correctly identified. In the case of ’de-
generacy’, a peptide can be generated by different proteins. Again, we follow those
information to specify the conditional probability model for peptide indicators Y
given protein indicators X.
We let pii,j = Pr(Yj = 1|Xi = 1) denote the probability that peptide j is correctly
identified conditional on its parent protein i being present. Let Cj denote the set of
proteins that could potentially generate peptide j. Notice that the probability that
peptide j is present in the digested sample is equal to the probability that at least
one protein in Cj generates it.
We have
Pr(Yj|X) = 1−
∏
i∈Cj
(1− pii,j)Xi (2.4)
This conditional probability pii,j might depend on certain peptide sequence spe-
cific information, such as amino acid content, charge, hydrophobicity and polarity
(see [29]). Ideally, incorporating those covariates that contain information about
the observability of peptides can help us accurately estimate peptide and protein
probabilities. Again, a logistic regression or Probit model can be a natural choice
to incorporate those relevant explanatory variables in a prior model for pii,j. Due to
the lack of those measurements in our data, we simply assume pii,j = pi, a constant
unknown parameter which has prior information assigned before MCMC steps.
The Fourth Stage: Pr(X)
Finally, we assume the prior model for the presence of protein i is a Bernoulli
distribution, i.e., P (Xi = 1) = qi. Here qi is the prior probability that protein
i is present. Again, prior knowledge on the presence/absence status of proteins
can be naturally incorporated in the prior model for qi. For example, if organism
level information is available, we can further specify another layer of model in the
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hierarchical framework that reflects protein/organism grouping information. Again,
due to the lack of this information in our study, we simply assume qi = q, a constant
unknown parameter that has prior information assigned before MCMC steps.
2.2.4 Bayesian Implementation and Bayesian False Discovery Rate
We employ MCMC methods to do the model fitting. We begin with prior spec-
ifications for the parameters. Recall that we have unknown parameters (µ0, σ0, ξ0)
in the GEV distribution f0, (µ1, σ1, ξ1) in the GEV distribution f1, τ , pi and q in
the latent stage models. Vague normal priors are assigned to the location parameter
µ0, µ1, shape parameter ξ0, ξ1, and an inverse gamma priors are assigned to σ0, σ1.
We also assign Beta(1, 1), i.e., uniform distribution on [0, 1], to the parameters pi, τ
and q.
Posterior inference for the model parameters is completed using Gibbs sampling
[35] with Metropolis-Hastings updating [36]. With the above hierarchical model
and prior setup, all the conditional distributions turn out to be of known standard
except for the GEV parameters in f0 and f1. (µ0, σ0, ξ0), (µ1, σ1, ξ1) are then updated
using Metropolis steps. Typically, random walk Metropolis with normal proposals is
adopted. The detailed MCMC steps are given in Appendix.
In particular, we collect posterior samples of the latent peptide indicators Yj.
The posterior correctness probability for each peptide is estimated by the posterior
sample proportion of Yj. The correctness probability for each protein is obtained in a
similar way. The associated posterior error probability (PEP, also referred to as local
false discovery rate) is defined as the probability of being incorrect, simply calculated
by subtracting posterior probability from one. For a given probability threshold pc,
peptides with PEPs lower than pc are decided to be positive identifications. The
Bayesian FDR (see [37] and [32]) associated with the above decision is estimated by
the average PEPs that are below pc.
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FDR(pc) =
∑
PEP<pc
PEP
#{PEP < pc}
A similar approach is easy to be applied to protein posterior PEPs. The Bayesian
FDR could be used to assess the protein level identifications by our approach.
2.3 Results
Our identification approach is applied to the SEQUEST output on the Shewanella
data described in section 2.1. The independence assumption among PSMs causes un-
derestimated FDR, i.e. over-estimated number of identification at a specific FDR
cutoff, which confronts with the rule of conservative estimation. Figure 2.6 shows
that, compared with the true FDR lower bound, there are more identified pep-
tides at the same Bayesian FDR estimated under PSMs independence assumption
(red curve), which obeys the conservative rule for FDR estimation. Meanwhile, the
Bayesian FDR estimated under PSMs dependence assumption (green curve) shows
its conservative character.
The number of PSMs incorporated into the model–R has an impact on peptide
identification. Figure 2.7 shows the positive trend between the number of identified
peptides versus R–the number of top PSMs candidates utilized in the model, at a
specific FDR cutoff 0.05. The same trend maintains at different FDR cutoffs.
Our approach that models the top 10 PSMs, which identifies more peptide fea-
tures than PeptideProphet under most of the circumstances except for estimated
FDR below 0.02, see Figure 2.8.
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Fig. 2.6. The effect of independence assumption towards FDR esti-
mation. Red curve is estimated Bayesian FDR under independence
assumption of PSMs on the same peptide, green curve is estimated
Bayesian FDR under dependence PSMs assumption of PSMs on the
same peptide, black curve is the true FDR lower bound.
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Fig. 2.7. The number of peptide identification vs the number of
PSMs used in the model at 0.05 FDR cutoff.
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Fig. 2.8. The number of peptide identification vs estimated FDR
using top 10 PSMs candidates. The green curve is generated by our
approach and the blue curve is given by PeptideProphet. The black
curve is associated with the true FDR lower bound
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2.4 Discussion
In our framework, protein level posterior probability could be estimated one layer
after obtaining peptide level posterior probability estimation. Hence protein level
inference such as PEP, Bayesian FDR and the comparison with empirical lower bound
FDR could be done in a similar way. However, due to the lack of result from other
protein level identification algorithms on this Shewanella dataset, no comparison is
carried on in the same fashion as comparison at peptide level with PeptideProphet.
Our model could also be applied to the AMT tag approach, where we would have
both MS/MS data as well as hi-resolution mass and elution time measurements.
The MS data with AMT tag could also be searched against AMT database with
matching scores returned. We need to normalize matching scores and model the
distribution of the correct and incorrect normalized matching scores as well as other
informative covariates. Four layers need to be constructed for score—AMT match,
AMT match—peptide, peptide—protein and protein. In order to run MCMC, prior
information also need to be determined for the parameters in each layer as well as in
the model of matching scores. After the simulation, posterior probability at peptide
level and protein level could be inference by sample proportion and then produce
Bayesian FDR estimation.
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3. A STATISTICAL APPROACH TO THE ALIGNMENT OF LC-MS/MS
SAMPLES
3.1 Introduction
3.1.1 Background
In LC-MS, each sample may have thousands of scans, each containing a mass
spectrum. The mass spectrum for a single MS scan can be summarized by a plot of
M/Z values versus peak area values. These data contains signals that are specific to
individual peptide. As a first step towards quantifying these peptides, features need
to be distinguished from background noise. One simple method is to employ a filter
on the peak’s signal-to-noise ratio relative to its local background. Each peptide
gives an envelope of peaks due to a peptide’s constituent amino acids. The presence
of a peptide can be characterized by the M/Z value corresponding to the peak arising
from the most common isotope, referred to the mono-isotopic mass.
3.1.2 Existing Alignment Methods
The goal of alignment is to match corresponding peptide features in the Scan
Number vs M/Z plot (see figure on p. 49 in section 3.3.2) from different experi-
ments. A time warping method based on raw spectrum for alignment of LC-MS
data was introduced by Bylund and others [16], which is a modification of the origi-
nal correlated optimized warping algorithm [17]. Wang and others [38] implemented
a dynamic time warping algorithm allowing every Retention Time (RT) point to be
moved. However, the LC-MS data have added dimension of mass spectral informa-
tion, so only mapping the retention time coordinates between two LC-MS files is not
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sufficient to provide alignment for individual peptide. Radulovic and others [19] per-
formed alignment based on (M/Z,RT) values of detected features. Their method first
divides the M/Z domain into several intervals and fitted different piece-wise linear
time warping functions for each M/Z interval. After the time warping, they applied
a “wobble” function to peaks and allow peaks to move (1-2% of total scan range) in
order to match with the nearest adjacent peaks in another file. Their method relies
on the (M/Z,RT) values of detected peptide features, it fails to take advantage of
other information in the raw image. Wang and others [38] proposed an alignment
algorithm, PETAL, for LC-MS data. It uses both the raw spectrum data and the
information of the detected peak features for peptide alignment.
In Section 3, two Shewanella data sets are obtained from Pacific Northwest Na-
tional Laboratory (PNNL) and were analyzed by SEQUEST on different days. SE-
QUEST correlates uninterpreted tandem mass spectra of peptides with amino acid
sequences from protein and nucleotide databases, which determines the amino acid
sequence and thus the protein(s) and organism(s) that correspond to the mass spec-
trum being analyzed. Based on the SEQUEST output files, each sample has thou-
sands of scans, and M/Z, peak areas and peptide identification information associ-
ated. It’s obvious that there’s some systematic error between the the two data sets
before alignment.
In this study, we first applied some filter criteria to choose data points matched
in both samples with high confidence, which are called “Anchor points”. We then
use these “Anchor points” in sample one as the baseline and modify the data points
in sample two, to make the “Anchor points” between the two samples aligned to-
gether, which means after alignment the “Anchor points” in both samples show up
at the same locations. The alignment algorithm is then generated to all the other
data points in sample two. Finally, statistical measurements of the performance of
alignment are given on sample level and regional level.
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In future study, we hope this alignment method can be applied to several samples
of one organism, and as a guide to justify the points with same peptide information
in different samples.
3.2 Methods
3.2.1 Anchor Points
In our method, for different experiments, we have the raw data analyzed by
SEQUEST. Based on the SEQUEST output files, each sample has thousands of
scans, M/Z, peak areas and peptide information. A sample record of data is given
in Table 3.1. Define a point with high probability that its peptide shows up in
SEQUEST output files as “Anchor points”.
Table 3.1
A sample record of SEQUEST output.
ScanNum MZ PeakArea NTE PassFilt SignalToNoiseRatio
8239 826.4 4.98E+06 2 1 25.1
ChargeState Xcorr DelCN RankXc Reference Peptide
3 7.9171 0 1 SO 2336 K.LA...GYVHA
In LC-MS, we need to distinguish the peptide features from the background
noise, the first step for doing this is MS peak detection. We employ a simple filter
routine on the Signal-to-Noise Ratio of a peak relative to its local background. In our
approach, in order to find peptides that exist in both samples with high confidence,
three filtering criteria are applied. The first criterion is PassFilt equaling to 1, the
second criterion is Number of Tryptic Ends (NTE) equaling to 2 and the third
criterion is Signal-to-Noise Ratio being greater than 10. PassFilt is a score that does
not come from by SEQUEST but is calculated from syn-fht summary generator using
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Xcorr, δCn , RankXc and the number of tryptic termini (NTT), where NTT is the
number of termini that conforms to the expected cleavage behavior of trypsin (i.e.
C-terminal to R and K). Note that K-P and R-P do not qualify as tryptic cleavages
because of the proline rule. However, the protein N-terminus and protein C-terminus
do count as tryptic cleavage sites. Values can be 0, 1, 2 with 2 = fully tryptic; 1 =
partially tryptic; 0 = Non tryptic. Any point associated with the same peptide in
both samples satisfied these three criteria is called “Anchor point”, see Figure 3.1.
3.2.2 Alignment Algorithm
“Anchor points” found from both samples differ on “Scan Number”, which repre-
sent elution (retention) time, on which we need to find some algorithm to make these
points in the two samples aligned, as well as on M/Z and Peak Area. Since the range
of Peak Area is not as the same magnitude as Scan Number or M/Z, a logarithm
transformation is applied. Let Si be the Scan Number for peak i, Mi be M/Z for peak
i, and Pi be the log(peak Area) for peak i. The data is normalized to zero-to-one
range by dividing normalization factors of Scan Number, M/Z, and log(Peak Area),
denoted as RX , RM and RP , which are the maxima of Scan Number, M/Z, and
log(Peak Area) across the two samples. The reason why we do normalization is that
due to the different scales of Scan Number, M/Z and log(Peak Area), the distances
can not be equally measured, for example, the scan number is very large compared
to the M/Z. The normalization could transform the three dimensional measurement
under the same scale and thus give equal weighting to all of them. The alignment
algorithm uses both the raw spectrum analyzed by SEQUEST and the detected peak
features for peptide alignment. Although in the two samples, the peaks with same
identified peptide information appear in different scan numbers due to systematic
bias, we assume that the scan numbers, M/Z and log(Peak Area) should not differ
much within the paired peaks.
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Fig. 3.1. Plot of anchor points embedded in both samples. Left
panel is for sample one and right panel for sample two.
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With the pool of “Anchor points” found between sample one and sample two,
we are able to locate the K nearest anchor points for peak i in sample two, where
the distance is defined by Euclidean metric considering the three dimensions of nor-
malized Scan Number, M/Z and log(PeakArea). With the defined metric, let Dij be
the distance between peak i and an arbitrary “Anchor point” j in the sample two,
Dij = (((Si − Sj)/RS)2 + (Mi −Mj)/RM)2 + (Pi − Pj)/RP )2.
Since each “Anchor point” in sample two is paired with an “Anchor point” in
sample one, let ∆S be be the averaged scan number differences across the K nearest
“Anchor point” pairs; let ∆M be the averaged M/Z differences across peak i’s K
nearest “Anchor points” pairs; and let ∆P be the averaged log(peak Area) differences.
Then we use the differences to modify peak i in sample two by adding (∆S,∆M ,∆P )
to (Si,Mi, Pi). ∆S = Si.1 − Si.2, ∆M = M i.1 −M i.2, ∆P = P i.1 − P i.2, where Si.1 is
the average over Scan Number of K “Anchor points” in sample one.
3.3 Real Data Example
3.3.1 Visualization of Alignment
In the Shewanella datasets, RS = 10606, RM = 1519.48, RP = 10.08476. The
data is firstly normalized with RS, RM and RP and then searched for “Anchor
points”. There are systematic bias between the differences on Scan number, M/Z
and log(Peak Area) of “Anchor points” from both samples before alignment. After
alignment, the differences should be randomly distributed around 0. We draw his-
tograms to compare the distance of “Anchor points” between the two samples before
and after alignment. Figures 3.2 and 3.3 are the histogram of Scan Number and
M/Z. The histogram of log (Peak Area) is shown in Figure 3.4 on page 48. The
histograms show that, after alignment, the differences on Scan Number, M/Z and
log (Peak Area) between the two samples are mostly around 0.
46
Fig. 3.2. Histograms of Scan Number of anchor points. Left panel
is for before alignment and right panel for after alignment.
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Fig. 3.3. Histograms of M/Z of anchor points. Left panel is for
before alignment and right panel for after alignment.
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Fig. 3.4. Histograms of Log(Peak Area) of anchor points. Left panel
is for before alignment and right panel for after alignment.
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Fig. 3.5. Scatter plot of Scan Number vs. M/Z on all data points.
Left panel is for before alignment and right panel for after alignment.
To visualize the alignment, scatters plots of Scan Number versus M/Z and Scan
Number log (Peak Area) on “Anchor points” before and after alignment are given
as Figures 3.5 and 3.6.
3.3.2 Global P-value for Alignment Performance
It is important to perform a statistical test to justify that after alignment, there
is no systematic difference across all the ”Anchor points” between the two samples.
Wilcoxon signed-rank test is applied on the differences on Scan Number, M/Z and
log(Peak Area) of the “Anchor points” between the two samples, before and after
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Fig. 3.6. Scatter plot of Scan Number vs Log (Peak Area) on all
data points. Left panel is for before alignment and right panel for
after alignment.
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alignment with K = 5. The null hypothesis is that the true location shift is equal to
0 while the alternative hypothesis is the true location shift is not equal to 0.
We have the following results: Before alignment Wilcoxon signed-rank test on
Scan Number of anchor point with continuity correction W = 537733, p-value ≤
2.2e − 16. After alignment Wilcoxon signed-rank test on Scan Number of anchor
point with continuity correction W = 2932224, p-value = 0.0986.
Before alignment Wilcoxon signed-rank test on M/Z of anchor points with con-
tinuity correction W = 142212, p-value = 0.1091. After alignment Wilcoxon signed-
rank test on M/Z of anchor point with continuity correction W = 265884, p-value
= 0.9049.
Before alignment Wilcoxon signed-rank test on log(Peak Area) of anchor point
with continuity correction W = 336362, p-value= 1.655e − 09. After alignment
Wilcoxon signed-rank test on log(Peak Area) of anchor point with continuity correc-
tion W = 281910, p-value = 0.6141.
So we conclude that the difference on Scan Number, M/Z and log(Peak Area)
of “Anchor points” after alignment in two samples has a common median 0, which
indicates our alignment approach is valid and effective to fulfill the alignment task.
3.3.3 Local P-values for Alignment Performance
We then generalize the single global p-value on the whole data set to local p-
values, realized by Wilcoxon sum rank test. For example, the entire span of Scan
Number versus Log (Peak Area) are divided into, for example, 10 X 10 small rect-
angular, the cutoffs on the margins are the 10%, 20%, · · · , 90% quantiles of Scan
Number and Log (Peak Area). Take a single rectangular for example, Wilcoxon sum
rank test is applied on Scan Numbers that fall into that single rectangular before
and after alignment and hence gives a p-value for that region. We repeat this on the
other 99 rectangular and obtain 100 p-values in total. The p-values on Log (Peak
Area) are calculated in a similar way. Figure 3.7 displays the histogram of the 100
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Fig. 3.7. Histogram of regional p-values on Scan number. Left panel
is for before alignment and right panel for after alignment.
p-values on Scan Number and Log (Peak Area). We can see that there are fewer
small p-values on Scan Number after alignment. The heat map on Scan Number
confirms that since there are less red but more yellow rectangular after alignment,
shown as in Figure 3.8
The regional division could be realized in three dimensional fashion, but due to
the limitation of data size, there would not be enough peaks in a large proportion
of three-dimensional cubes to do the Wilcoxon sum rank test. However, if the data
size is sufficient, the localization of p-value would be more precise and valuable to
evaluate the effectiveness of the alignment algorithm.
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Fig. 3.8. Heat map of regional p-values on Scan number. Left panel
is for before alignment and right panel for after alignment.
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3.4 Discussion
One advantage of our method is that it allows statistical assessment of alignment
performance. We could statistically evaluate the performance of our methodology
with other alignment algorithms on some data set that has peptide identification
with high confidence.
The statistical confidence measure of our method was given on sample level. We
expanded it to region level and the future work would be developing peptide level
statistical confidence measure and pass it to downstream quantitative analysis.
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4. A HYBRID APPROACH TO PROTEIN DIFFERENTIAL EXPRESSION IN
MASS SPECTROMETRY-BASED PROTEOMICS
4.1 Introduction
A key goal of quantitative mass spectrometry-basad proteomics is statistical in-
ference on differential protein expression. Quantitative information is derived froe
spectral peak intensities that are identified as having come from one of a protein’s
constituent peptides. Statistical procedures for differential protein expression are
naturally constructed in the context of regression or ANOVA [39], or as a “rollup”
problem [23].
However, intensity-based procedures are challenged by the presence of widespread
missing intensities. It is typical for 20-40% of the total collection of attempted
measurements to be missing; that is, in a matrix with all identified peptides in the
rows, samples in the columns, 20-40% of the matrix cell entries are empty. With
standard regression or ANOVA procedures, peptides with missing values must either
be removed from the analysis, or their missing values must be imputed. There will
typically be very few peptides with no missing values, so filtering peptides in this
way results in a much less informative data set. Furthermore, previously-published
reports indicate that the vast majority of missing values are the results of censoring of
absent or low-abundance peptides [24]. This means that simple imputation routines
are not appropriate [25].
Parametric imputation and other specialized methodology can be employed to
enable intensity-based inference with lessened information loss. However, some in-
formation loss is inevitable. In particular, “one-state” (or nearly so) peptides, those
for which there are many observed intensities in one comparison group but few in
another comparison group, are not amenable to an intensity-based analysis; not lim-
56
ited to the two-class problem. As a result, such peptides are typically filtered out
of an intensity-based analysis. A protein that is always present in a diseased state,
say, and never in the healthy state would be of great biological interest, so it is
unfortunate if our statistical methodology can not identify such a protein.
An alternative to an intensity-based analysis is a “presence / absence” analysis, in
which peak intensities are digitized into binary measurements depending on whether
a peak was observed or not. This is analogous to the spectral counting approach in
MS/MS studies [40], where a peptide is quantified by the number of fragmentation
spectra assigned to it. Data collected in our laboratory does not necessarily have
MS/MS fragmentation data associated with at, instead being obtained according to
the Accurate Mass and Time (AMT) tag pipeline [18]. Still, we have information on
whether or not a particular peptide was measured in each sample.
While presence / absence analysis is better-suited to finding one-state proteins, it
necessarily has less statistical power to detect abundance differences in proteins with
little to moderate missingness. Ideally, protein differential expression analysis would
simultaneously target proteins of both types, resulting in a single list of differentially
expressed proteins, with a single associated false discovery rate (FDR). A hierarchical
Bayesian model would be well-suited to this purpose, but such techniques are com-
plex, computationally intensive, and hence amenable to high-throughput pipelines.
We present a hybrid analysis protocol that consists of two stages: (i) intensity-
based analysis, and (ii) a presence / absence analysis. The results of each are merge‘
to create a single collection of “interesting proteins” po which we use novel method-
ology to apply a single FDR. This enables the researcher to detect more information
from a quantitative proteomic data set than would be achievable by either approach
alone, while still maintaining an interpretable measure of overall statistical confi-
dence. For the proposed hybrid analysis protocol, we demonstrate the following: (a)
Resulting FDR estimates are conservative, (b) One-state proteins are consistently
selected as differentially expressed, and (c) The number of differentially expressed
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proteins selected at a specified FDR exceeds that either intensity-based or presence
/ absence analysis alone.
4.2 Methods
4.2.1 Data
Diabetes
These data are as previously described [21]. In order to minimize the number of
sibling peptides with large missingness proportion differences, we use PeptideSieve
[41] to filter peptides whose amino acid sequences are unlikely to be detected by MS.
554 peptides are filtered out before carrying on any further analysis.
Simulation
We carried out simulation studies as follows, to investigate the operating charac-
teristics of our methodology at both peptide and protein levels. Peptide-level data
were generated from a Binomial model, under the same conditions as the diabetes
data (two comparison groups with 10 samples in each). Presence probabilities in
group one took the values on p1 = 0.2, 0.3, 0.4, 0.5. Half of the group-two peptides
were assigned the same presence probabilities as their group-one counterparts. In
the other half, differential presence probabilities were created, with probability dif-
ferences (comparing group two to group one) of pd = p2− p1 = 0.1, 0.2, · · · , 0.9− p1.
Separate simulations were carried out for each of the group-one presence probability
values with even replications on different pd settings. Similarly, for protein-level data,
the number of peptides per protein was randomly selected to range between 1 and
30. Protein-level presence probabilities also took the values p1 = 0.2, 0.3, 0.4, 0.5 and
pd = p2 − p1 = 0.1, 0.2, · · · , 0.9 − p1. For each constituent peptide, the group-one
peptide-level presence probability equaled the protein-level probability multiplied
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by a randomly-selected number between 0 and 1 (to allow for different levels of
detectability for peptides of the same protein). Peptide-level differential presence
probabilities were handled as described for the peptide-level simulation above. Fi-
nally, to simulate data for use by the hybrid method, with both peak intensities
and presence / absence indicators, we randomly generated intensities from a Nor-
mal distribution with parameters chosen to mimic the diabetes data. Missingness
proportions took the values 10%, 20%, 30%, and 40%, with missingness created
by censoring the lowest corresponding percentages of peptide intensities. As in the
above simulations, half of the peptides / proteins were given differential expression,
now defined in terms of mean intensity levels. Differential intensity magnitudes took
both low-magnitude values of 1, 2, as well as high-magnitude values of 5, 10, all on
the log scale.
4.2.2 Logistic Model for Protein Presence / Absence
Logistic regression is a natural analysis method for presence / absence data, given
their binary nature. Specifically, let Yijkl be the indicator for whether a peak was
observed for peptide j of protein i in comparison group k and sample l. Then, we can
say Yijkl ∼ Binomial(1, pijk) for l = 1, 2, . . . , nk, where nk is the number of samples
in comparison group k. A simple logistic regression model would then be
logit(pijk) = Proti + Pepij + Grpik. (4.1)
Here, Proti represents the overall (across all comparison groups) log odds of peak
presence for protein i, Pepij is the effect of peptide j of protein i (assumed to be
the same across all k comparison groups), and Grpik is the protein-level effect of
comparison group k in protein i. Usual sum-to-zero constraints apply; namely,∑mi
j=1 Pepij = 0 and
∑K
k=1 Grpik = 0 for i = 1, 2, . . . ,M , where M is the total
number of proteins in the data.
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For the purposes of comparing protein presence probabilities across comparison
groups, the parameters of interest are the Grpik, i = 1, 2, . . . ,M . For example, in
the diabetes data, K = 2, with k = 1, 2 corresponding to the diabetic and control
groups, respectively. Hence, Grpi1−Grpi2 is the log odds ratio for protein i, comparing
diabetics to controls. Testing for a difference in presence probabilities corresponds
to testing the null hypothesis that Grpi1 − Grpi2 = 0; given the model’s sum-to-
zero constraints, this is equivalent to the null hypothesis that Grpi1 = Grpi2 = 0.
Of course, the model is not restricted to the two-class case and can naturally be
generalized to the K-class case, in which the corresponding null hypothesis is that
Grpi1 = Grpi2 = · · · = GrpiK .
Unfortunately, logistic regression is not well-suited in practice to the analysis of
presence / absence data. In particular, biologically-interesting proteins are liable to
be missed entirely, due to inherent limitations of the methodology. Consider a “one-
state” protein, present in all samples for one comparison group, absent in all samples
for the other comparison groups. From a biological perspective, this would be a very
interesting protein. However, in logistic model, the p-value for such a protein will
tend to be reported as nearly equal to one, meaning that the protein would not be
selected as differentially expressed under any reasonable criteria.
A simple scenario illustrates this problem. Consider a “one-state” protein with
just a single peptide. In logistic regression, the assumed variance-covariance matrix
for regression coefficients is (X ′WX)−1, where X is the model matrix, and W is
diagonal with entries pk(1 − pk), with pk the presence probability in comparison
group k, k = 1, 2. For comparison groups in which no peaks were observed, the
estimated value of pk is zero, making the corresponding entry in W equal to zero.
This results in an overestimation of the standard error for the group effect model
term, hence an understatement of statistical significance for that protein’s group
effect. In the diabetes data, for example, “one-state” proteins are assigned p-values
of one.
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4.2.3 Peptide-level Exact Test
In light of the logistic regression limitations, we propose an exact procedure for
testing for differences in presence / absence between two comparison groups. Let
yjk · =
∑n
l=1 yjkl be the number of observed peaks for peptide j in comparison k,
k = 1, 2. We use Tj = |yj1 · − yj2 · | as the peptide-level test statistic. Based on
the Binomial probability model, the exact sampling distribution of Tj under the null
hypothesis H0 of no difference in presence probabilities can be written as
PrH0(Tj = t) =
n1−t∑
m1=0
n2∑
m2=m1+t
B(m1;n1, pj0)×B(m2;n2, pj0)
+
n2−t∑
m2=0
n1∑
m1=m2+t
B(m1;n1, pj0)×B(m2;n2, pj0)
where B(m;n, p) is the Binomial PMF at m, with n trials and probability of success
p, and pj0 is the shared probability of peak presence for both groups. Thus, based
on an observed statistic of tj, the p-value is
∑
t≥t PrH0(Tj = t). In practice, we need
only to estimate the shared presence probability under the null hypothesis, pj0, in
order to approximate the p-value for a given peptide. We estimate pj0 with a pooled
sample proportion, resulting in pˆj0 =
∑
k nk ˆpjk∑
k nk
, where pˆjk = yjk · /nk, K = 2.
As an example, consider a “one-state” peptide, present in all samples of one
group but in no samples of the other group, in the diabetes data. Whereas logistic
regression reports a p-value of one, the exact test correctly highlights the peptide as
statistically significant. Specifically, the test statistic Tj equals 10, and pˆj0 = 0.5, so
the p-value is computed as 2×B(10; 10, 0.5)×B(0; 10, 0.5) < 0.0001
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4.2.4 Protein-level Bootstrap Test
For inference at the protein level, there is the added challenge of multiple peptides
belonging to the same peptide. To incorporate all sibling peptides into a single test
for differential presence probabilities, we use the following test statistic:
TMi =
∣∣∣∣ ∑
j=1,...,mi
κij (yij1 · − yij2 · )
∣∣∣∣ (4.2)
where i is protein index, j is peptide index, and k is comparison group index, i =
1, 2, . . . ,M , j = 1, 2, . . . ,mi, k = 1, · · · , K, K = 2. The statistic in (4.2) is a
weighted average of observed presence difference on each sibling peptide. For the
weighting term κij, we use κij = yij · · /
∑
j yij · ·
A parametric bootstrap procedure [42] is used to approximate the sampling dis-
tribution of the TMi under null hypothesis setting as follows. Firstly the Binomial
parameters pijk are estimated, for which two approaches are considered. The first
approach simply uses the sample proportion for peptide j of protein i in compari-
son group k being present, which needs 2 × mi parameter estimation per protein.
Alternatively, we approaching the problem by inducing some structure between the
pijk, assuming that pijk = pik × dij, where pik is the overall presence probability
for protein i in comparison group k, and dij is the “detectability” probability (the
probability that a particular ion species is detected by the LC-MS instrument) for
peptide j of protein i. This assumption of structure translates to an assumption
that the detectability of a peptide does not differ between comparison groups. Since
detectability is a function of chemical composition rather than abundance [41], this
seems a reasonable assumption. After introducing the structure assumption the
number of parameters per protein to be estimated reduces from K ×mi to K +mi.
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With the second approach, the presence probability pik of protein i in group k
is estimated by averaging the presence proportion of its top 10% most prevalent
peptides.
pˆik =
∑
j∈{top10%}
pˆijk/#{top 10% peptides }
The rationale here is that, for these most prevalent peptides, the detectability
probability will be close to one, making pijk ≈ pik. Then pˆik is used to estimate dij
as dˆij =
1
K
(
ˆpij1
pˆi1
+ · · ·+ ˆpijk
ˆpik
)
, where pˆijk and pˆik are the sample presence proportions.
Since we have pˆik and dˆij, according to the equation pijk = pik×dij, the null sam-
pling distribution of our test statistic could be generated by parametric bootstrap.
Under the null hypothesis setting, the presence probabilities of protein i across K
comparison groups are the same and set to be pi0. In two group case, pi0 = pi1 = pi2
and pˆi0 =
pi1+pi2
2
. Thus, for peptide j of protein i in group k, nk zeroes or ones are
generated from the Binomial distribution with probability pˆijk = pˆik × dˆij, k = 1, 2.
We run B bootstrap iterations and compute the test statistic (4.2), TMb in each
iteration. The p-value is then computed as the proportion of bootstrap test statistic
values being as or more extreme as our observed TMi value:
p-value =
# {TMb ≥ TMi}
B
.
4.2.5 False Discovery Rate (FDR) Estimation
The false discovery rate (FDR) associated with a list of features selected at a
p-value cutoff cp [43] is the expected number of false positives F out of the total
number of selected features S:
FDR(cp) = E
[
Fcp
Scp
]
≈ E
[
Fcp
]
E
[
Scp
] (4.3)
The denominator can be replaced simply with the observed number of selected
features. The traditional approach to estimate the numerator is to exploit the ex-
pected uniform sampling distribution of the null p-values [43]. In particular, we can
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estimate E
[
Fcp
]
by M × pˆi0 × cp, where M is the total number of features and pˆi0
is the estimated proportion of null features out of the total M features. However,
as our test statistic is discrete, its null sampling distribution is not necessarily Uni-
form. As an example, Figure 4.1 shows a simulated null sampling distribution for
peptide-level test statistics, in which the shape of the null sampling distribution is
quite non-Uniform and could depend on many factors, including the number of pep-
tides of a protein, the sample size of each comparison group and the overall number
of observed peaks of a protein.
Peptide-level FDR Estimation
An alternative way to estimate the numerator in equation (4.3) is as a weighted
summation over all peptides on their estimated null right-tail probabilities at p-value
cutoff cp:
Eˆ[Fcp ] =
∑
j
wjĈDFj0(cp)
where wj is a weight (number between 0 and 1) constructed to be close to one for
null peptides. If we assign all wj with value 1, i.e. each peptide is given weight 1,
the corresponding FDR estimation is called “unweighted” estimation. ˆCDFj0 is the
estimated null p-value cumulative distribution function (CDF) for peptide j. The
estimate of CDFj0 is derived from an estimate of the null probability mass function
(PMF) for peptide j:
P̂MFj0(cp) = Pˆ r0(Tj = Tj(cp))
=
∑
Tj=Tj(cp)
Pr(Yj1|pˆj0)× Pr(Yj2|pˆj0)
where pˆj0 = (Yj1 + Yj2)/(n1 + n2).
For the wj, we use
wj =
 1 if P̂MFj0(cp) ≥ P̂MFj1(cp)0 if otherwise
64
Fig. 4.1. P-value histograms of simulated null peptides with
shared presence probabilities of 0.2, 0.3, 0.4, 0.5 across each compari-
son group.The null sampling distribution is non-uniform, due to the
discrete nature of the test statistic.
We therefore estimate the peptide-level FDR as
F̂DRpep(cp) =
∑
j wjĈDFj0(Tj(cp))
# {p− value ≤ cp}
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Protein-level FDR Estimation
Our simulation studies indicate that for most settings, the p-value of the test
statistic for multi-peptide protein (4.2) is approximately uniformly distributed under
null hypothesis setting, especially when there are moderate overall levels of presence
(data not shown) and moderate number of sibling peptides in a protein. Because of
this, we use the standard [43] method for FDR estimation. Namely, at p-value cutoff
cp, we estimate the FDR as
F̂DRpro(cp) =
M × pˆi0 × cp
# {p-values ≤ cp}
where M is the total number of proteins, and pˆi0 is the estimated proportion of null
proteins, which could also be seen as a uniform weight across proteins wj = M × pˆi0
across all proteins”. We estimate pi0 by fitting a smooth lowess curve to the values
of pˆi0(λ) =
#{p−values>λ}
M(1−λ) as λ→ 1 [43].
Figure 4.2 shows the histogram of p-values from bootstrap on simulated mixed
null and alternative five-peptide proteins, which has a uniform shape right tail that
indicates the appropriateness of using the standard method (2003) to estimate FDR.
Mixed Single-peptide and Multi-peptide Protein Level FDR Estimation
In practice, both single-peptide proteins and multi-peptide proteins are usually
mixed in a data set, for which we’ve developed p-value and FDR estimation sepa-
rately. The two sets of p-value are left as is while a unified FDR estimate needs to be
generated based on the pooled set of p-values. The numerator of FDR for mixed case
is given by summing up the estimation of expected number of false positive features
for single-peptide protein and multi-peptide proteins, as indicated in the above two
sections, and the denominator is the number of selected features based on the p-value
pool.
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Fig. 4.2. P-value histograms of simulated null peptides with
shared presence probabilities of 0.2, 0.3, 0.4, 0.5 across each compari-
son group.The null sampling distribution is non-uniform, due to the
discrete nature of the test statistic.
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F̂DRmix(cp) =
E(#{FPIcp})
#{p-value ≤ cp}
=
∑
j wjĈDFj0(Tj(cp)) +M × pˆi0 × cp
#{p-valuess ≤ cp or p-valuesm ≤ cp}
where p-valuess are the p-values for single peptide proteins and p-valuesm are those
for multi-peptide protein
4.2.6 Hybrid Analysis Incorporating Both Presence / Absence and Intensity
Measurements
The above methodology has dealt only with presence / absence data, from which
peak intensity measurements are excluded. The rationale for simplifying peak in-
tensity measurements to presence / absence is that it better enables discovery of
“one-state” (or similar) proteins. However, statistical information is lost by throw-
ing out intensity measurements, which would translate to decreased statistical power
to detect differentially expressed proteins that differ in terms of abundance but not
presence / absence. Thus, we would ideally incorporate both peak intensity and
presence / absence information into a differential expression analysis. One simple
way to do this is to carry out separate intensity-based and presence / absence-based
analysis, select proteins at a specified FDR from each analysis, then report the union
of the two resulting protein lists. However, while we might intuitively expect a small
FDR for the resulting list of proteins, we will not generally be able to assign an ac-
tual FDR estimate. In what follows, we derive a FDR estimate for the union list of
differentially expressed proteins. Thus, taken together, the methodology presented
here allows the researcher to select a list of differentially expressed proteins, some
based on intensity and others based on presence / absence, to which an overall FDR
estimate can be assigned.
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We use a single p-value threshold cp for both intensity measurements and pres-
ence / absence; so, a protein is selected if either of its intensity-based and presence
/ absence p-values are less than cp. Intensity-based p-values are derived from re-
gression models and censored likelihoods from our prior work [21]. Let p-valueb and
p-valuep correspond to the binary presence / absence and peak intensity measure-
ments, respectively. The FDR for a hybrid analysis can then be estimated by
ˆFDRh(cp) =
∑
iwiPˆ r0
(
p-valuebi ≤ cp ∪ p-valuepi ≤ cp
)
# {p-valuesb ≤ cp or p-valuesp ≤ cp}
=
∑
iwiPˆ r0
[
cp + (1− cp)Pˆ r (TMi ≥ TMi(cp))
]
# {p-valuesb ≤ cp or p-valuesp ≤ cp}
We set the weight wi equal to the average of the binary weight and the uniform
weight derived from Storey and Tibishirani’s FDR estimation scheme in the intensity-
based method [21].
4.3 Results
4.3.1 Peptide-level Simulation Result
Figure 4.3 shows the number of significant single-peptide proteins versus FDR,
based on the proposed peptide-level presence / absence methodology. The particular
simulation scenario displayed in the figure has p1 = 0.3, with a random mixture of
differential presence / absence, ranging over pd = 0.1, 0.2, . . . , 0.6. The unweighted
FDR estimate is very conservative, resulting in many fewer significant peptides at a
given FDR estimate, relative to the true FDR curve. The binary weighting improves
this somewhat, resulting in greater power while maintaining conservative FDR esti-
mate. Results for other values of p1 are similar (data not shown). Table 4.1 shows
Type I error and power for the proposed presence / absence methodology applied
to simulated single-peptide and 5-peptide proteins. As would be expected, we have
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Fig. 4.3. Numbers of significant single-peptide proteins versus FDR
for the proposed protein-level methodology, on simulated data with
p1 = 0.3 and a mixture of differential presence / absence levels. The
weighted FDR estimate is conservative.
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greater power to detect differential expression when there are multiple peptides in a
protein.
Table 4.1
Peptide-level error rates and power with p1 = 0.2, 0.3, 0.4, 0.5 and
pd = 0.0, 0.1, . . . , 0.7.
pd = p2 − p1 p1 = .2 p1 = .3 p1 = .4 p1 = .5
pd=0.0 0.053 0.051 0.050 0.047
pd=0.1 0.069 0.065 0.058 0.048
pd=0.2 0.133 0.122 0.120 0.110
pd=0.3 0.240 0.232 0.210 0.182
pd=0.4 0.381 0.365 0.353 0.348
pd=0.5 0.512 0.461 0.430 *
pd=0.6 0.720 0.677 * *
pd=0.7 0.874 * * *
4.3.2 Protein-level Simulation Result
Figure 4.4 shows the number of significant five-peptide proteins versus FDR,
based on the proposed protein-level presence / absence methodology. The simula-
tion scenario in this figure is similar to that in Figure 4.3, now with each protein
having 5 constituent peptides. In this case, ”weighting” is carried out using the
standard pˆi0 estimate, again resulting in conservative FDR estimate. The pictures
for different values of p1, as well as for different numbers of constituent peptides, are
not qualitatively different (data not shown).
Table 4.2 shows Type I error and power for the proposed presence / absence
methodology applied to simulated five-peptide proteins. As would be expected, we
have greater power to detect differential expression when there are multiple peptides
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Fig. 4.4. Numbers of significant five-peptide proteins versus FDR
for the proposed protein-level methodology, on simulated data with
p1 = 0.3 and a mixture of differential presence / absence levels. The
weighted FDR estimate is conservative.
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in a protein.The pool of number of peptides of a protein is 5, 10, 15, 20, 25, the pres-
ence probability of proteins take value among p1 = 0.2, 0.3, 0.4, 0.5 and pd = p2−p1 =
0.1, · · · , 0.9− p1, peptide detectablity is set to vary among 0.9, 0.7, 0.5, 0.1, 0.01.
Table 4.2
Protein-level error rates and power with p1 = 0.2, 0.3, 0.4, 0.5 and
pd = 0.0, 0.1, . . . , 0.7.
pd = p2 − p1 p1 = .2 p1 = .3 p1 = .4 p1 = .5
#pep=5
pd=0.0 0.051 0.052 0.050 0.054
pd=0.1 0.196 0.158 0.136 0.096
pd=0.2 0.486 0.404 0.388 0.352
pd=0.3 0.778 0.734 0.710 0.692
pd=0.4 0.960 0.924 0.910 0.908
pd=0.5 0.994 0.990 0.990 *
pd=0.6 1.000 1.000 * *
pd=0.7 1.000 * * *
4.3.3 Mixed Single-peptide Protein and Multi-peptide Protein Simulation Result
Figure 4.5 shows the number of significant mixed proteins versus FDR, based on
the proposed protein-level presence / absence methodology. The simulation scenario
in this figure is similar to that in Figure 4.4, now with proteins having 1, 2, · · · , 5
constituent peptides. In this case, ”weighting” is borrowing the single-peptide weight
and multi-peptide weight for the corresponding proteins, again resulting in conser-
vative FDR estimate. The pictures for different values of p1, as well as for different
numbers of constituent peptides, are not qualitatively different (data not shown).
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Fig. 4.5. Numbers of significant mixed proteins versus FDR for the
proposed protein-level methodology, on simulated data with p1 = 0.3
and a mixture of differential presence / absence levels. Constituent
peptide number varies from one to five. The weighted FDR estimate
is conservative.
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4.3.4 Hybrid Approach Simulation Result
Our final simulation contains a combination of single- and multi-peptide proteins,
a variety of differential expression magnitudes, with a sample size of 10 in each of
the two comparison groups. In this case, peak intensities were simulated, from which
presence / absence data were obtained, to reflect the intended real-world setting in
which both intensity-based and binary presence / absence information is available.
Figure 4.6 compares the proposed hybrid approach with both our “qualitative” (pres-
ence / absence-based) and previously-published “quantitative” (intensity-based) [21]
methodology. All FDR estimates are conservative, and the hybrid approach results
in greater numbers of significant proteins, at a given FDR, than either of the presence
/ absence- or intensity-based approaches. Table 4.3 lists the number of differentially
expressed proteins at an estimated FDR cutoff of 0.05, for a variety of simulation
settings (varying the proportion of missing data as well as the amount and magnitude
of differential expression). The results are consistent with those shown in Figure 4.6.
Thus, by combining a traditional intensity-based analysis with a presence / absence
analysis, we are able to supplement our findings with additional proteins of interest;
these would potentially include “one-state” proteins.
4.3.5 Diabetes Data
We found substantial differential expression overall in the diabetes experiment.
The original data set is comprised of 177 proteins containing 1396 peptides.In binary-
based method, after initial filtering, we were left with 841 peptides and all the 177
proteins, among which there are 105 multi-peptide proteins and 72 single peptide
proteins. In intensity-based method, 44 proteins are filtered out. On the 133 proteins
that have p-values from both methods, 76 are identified by intensity-based algorithm,
55 are identified by binary-based algorithm and 88 are identified by hybrid method,
at estimated FDR 0.05. At estimated FDR 0.10, 89 are identified by intensity-based
75
Fig. 4.6. Numbers of significant peptides versus FDR for the pro-
posed peptide-level methodology, on simulated data with p1 = 0.3
and a mixture of differential presence / absence. The weighted FDR
estimate is conservative.
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Table 4.3
Number of identified features at estimated FDR level of 0.05 ob-
tained from binary-based method, intensity-based method and hy-
brid method under a variety of simulation settings. The hybrid ap-
proach consistently results in greater numbers of differentially ex-
pressed proteins.
Low mag. 25% dif 50% dif
Method/Miss 10% 20% 30% 40% 10% 20% 30% 40%
Quantitative 313 313 166 174 697 630 488 136
Qualitative 218 263 301 299 490 587 612 641
Hybrid 358 387 326 356 743 685 657 609
High mag.
Quantitative 422 349 281 114 1010 900 668 547
Qualitative 491 514 530 519 812 998 1011 1033
Hybrid 525 537 539 503 1036 1080 1055 1084
algorithm, 64 are identified by binary-based algorithm and 100 are identified by
hybrid method
Figure 4.7 compares the proposed hybrid approach with both presence / absence-
based and intensity-based methodology on the diabetes data set. The X axis is FDR
estimate and the y axis is the number of identified proteins at corresponding FDR.
the hybrid approach results in greater numbers of significant proteins, at a given
FDR, than either of the presence / absence- or intensity-based approaches.
4.4 Discussion
The proposed presence / absence-based methodology is designed to enable the
detection of “one-state” (or similar) proteins that are not amenable to traditional
intensity-based methods. Furthermore, we have proposed a hybrid approach that
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Fig. 4.7. Numbers of significant proteins versus FDR estimates on
diabetes dataset by presence/absence based method, intensity based
method and hybrid method
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combines both intensity- and presence / absence-based analysis of a data set, together
with FDR estimation of the combined list of differentially expressed proteins. The
proposed hybrid approach was demonstrated to outperform either of the intensity-
or presence / absence-based methods alone.
An obvious limitation to our work is its applicability to only two comparison
groups. A regression-based implementation would be more generalizable, and we
intend to pursue this in our future work. The choices of weights in the peptide-level
and hybrid methods could undoubtedly be improved upon as well; all FDR estimates
are quite conservative.
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5. SUMMARY
In the Section 2, the fully Bayesian hierarchical modeling successfully identifies
peptide and protein in a unified framework and detect more peptides than Peptide-
Prophet at most of the FDR cutoff values. This is owe to modeling the top R ranked
peptide spectrum matches to a MS fragmentation pattern with a collections of dis-
criminant features, allowing for dependence among the list candidates, incorporating
decoy search results to normalize target search score and selecting objective criteria
for the evaluation of the FDR at peptide level.
In the Section 3, one advantage of our algorithm is that it allows statistical assess-
ment of alignment performance on elution time, peak intensity and M/Z values uti-
lizing highly-confidently identified peptide information located as “Anchor points”.
The statistical confidence of our method is measured on sample level, generalized to
region level and then passed to downstream quantitative analysis. The future work
is to localize statistical confidence measurement to peptide level.
In the Section 4, the proposed presence / absence-based methodology is designed
to enable the detection of “one-state” (or similar) proteins that are not amenable to
traditional intensity-based methods partially due to large scale of missingness that
can’t be solved by traditional imputation. Furthermore, we have proposed a hybrid
approach that combines both intensity- and presence / absence-based analysis of a
data set, together with FDR estimation of the combined list of differentially expressed
proteins. The proposed hybrid approach was demonstrated to outperform either of
the intensity- or presence / absence-based methods alone.
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APPENDIX A
Bayesian Implementation:
• WXi : a latent variable such that P (Xi = 1) = Φ(WXi > 0)
• W pii,j: a latent variable such that P (Yj = 1|Xi = 1) = pii,j = Φ(W pii,j > 0)
• WZk,r: a latent variable such that P (Zk,r = 1|Ypep(k,r) = 1) = Φ(WZk,r) > 0
• The first stage: a multi-component mixture model for discriminant
scores
Sample Zk from 1, · · · , Rk + 1 with probability (pk,1, · · · , pk,Rk+1),
where pk,r =
ppriork,r f1(sk,r)f0(sk,r)∑Rk
r=1 p
prior
k,r f1(sk,r)f0(sk,r)+p
prior
k,0 f0(sk)
for r = 1, · · · , Rk and pk,Rk+1 =
1−∑Rkr=1 pk,r. Zk,r is obtained directly given the sample of Zk
• The second stage: Pr(Z|Y)
If for any r ≤ Rk, Zk,r = 1, let Ypep(k,r) = 1, draw a positive W pipro(k,r),pep(k,r)
from a truncated normal with mean µy and SD = σy and draw a positive
WZk,r from a truncated normal with mean µz and SD = σz.
Else if for any r ≤ Rk, Zk,r = 0, sample r from 1, · · · , Rk + 1 with probability
Pr(pep(k, r) = 1|Zk,r = 0) = Pr(Ypep(k,r)=1)∗(1−τ)Pr(Ypep(k,r)=1)∗(1−τ)+1−Pr(Ypep(k,r)=1) when r ≤
Rk, and Pr(pep(k,Rk+1) = 1|Zk,r = 0) = 1−
∑Rk
r=1 Pr(pep(k, r) = 1|Zk,r =
0).
– If the sampled r ≤ Rk, draw a positive W pipro(k,r),pep(k,r) from a truncated
normal with mean µy and SD = σy, draw a negative W
Z
k,r from the
truncated normal with mean µz and SD = σz and set the corresponding
Ypep(k,r) = 1.
– Otherwise draw negative WZk,r for r in 1, · · · , Rk + 1 from a truncated
normal with mean µz and SD = σz, set Ypep(k,r) = 0 for all r in
1, · · · , Rk.
88
• The third and fourth stage: Pr(Y|X) and Pr(X)
Let j = pep(k, r), search for the indices of proteins Ij that could produce Yj.
If there is only one protein in Ij, substitute Ij with i.
– If Yj = 1, let Xi = 1, draw a positive W
X
i from a truncated normal
with mean µx and SD = σx.
– Else sample Xi from 0, 1 with probability Pr(Xi)(1− pii,j), 1− Pr(Xi)
since P (Xi = 1|Yj = 0) = P (Xi)(1−pii,j)P (Yj=0) , P (Xi = 0|Yj = 0) =
1−P (Xi)
P (Yj=0)
,
where P (Xi) and pii,j have prior information and are updated through
WXii and W
pi
i,j in each MCMC iteration.
If Xi = 1, draw a negative W
pi
i,j from a truncated normal with µy and σy,
otherwise, keep W pii,j un-updated
If there are nj > 1 proteins in Ij, list all the 2
nj possible combinations of the
proteins and their probability of generating peptide Yj. For 1 ≤ l ≤ 2nj ,
take Cjl , the l th combination of Ij for example.
P (XiCjl |Yj = 1)
=
P (Yj = 1, XiCjl)
P (Yj = 1)
=
P (Cjl)P (Yj = 1|Cjl)
P (Yj = 1)
∝ [ ∏
iCjl
P (Xi)
∏
iIj\Cjl
(
1− P (Xi)
)−∏
iCjl
P (Xi)(1− pii,j)
] ∏
iIj\Cjl
1− P (Xi)
Pr(XiCjl |Yj = 0)
=
Pr(Yj = 0, XiCjl)
Pr(Yj = 0)
=
Pr(Cjl)Pr(Yj = 0|Cjl)
Pr(Yj = 0)
=
∏
iCjl
Pr(Xi)(1− pii,j)
∏
iIj\Cjl (1− Pr(Xi))
Pr(Yj = 0)
∝
∏
iCjl
Pr(Xi)(1− pii,j)
∏
iIj\Cjl
(1− Pr(Xi))
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– If Yj = 1, each combination’s probability conditional on peptide Yj
being present is proportional to its numerator in the above formula,
based on which one combination Cjl is sampled with probability
(
∏
iCjl
P (Xi)
∏
iIj\Cjl
(1− P (Xi))−
∏
iCjl
P (Xi)(1− pii,j))
∏
iIj\Cjl
1− P (Xi)
For each protein Xi in the sampled combination Cjl , set Xi = 1, draw
positive WXii for from truncated normal with mean µx and SD = σx.
For each protein XiIj\Cjl , set Xi = 0, draw negative WXii for from the
same distribution.
– If Yj = 0, randomly sample one combination Cjl out of the 2
nj com-
binations with probability
∏
iCjl
Pr(Xi)(1− pii,j)
∏
iIj\Cjl (1−Pr(Xi))
For each protein Xi in the sampled combination Cjl , set Xi = 1, draw
negative WXii for from truncated normal with µx and SD = σx, draw
positive W pii,j from a truncated normal with µy and SD = σy. For
each protein XiIj\Cjl , set Xi = 0, draw negative WXii from the same
truncated normal, keep W pii,j unchanged.
• q = pnorm(µx), pi = pnorm(µy), τ = pnorm(µz) are assigned normal priors and
are updated with the MCMC sample mean of WXi ,W
pi
i,j,W
Z
k,r. σx, σy, σz are
assigned inverse-gamma prior and are updated with sample standard deviation
of WXi ,W
pi
i,j,W
Z
k,r.
After sufficient rounds of iterations, the posterior probability of peptide j could
be estimated by the sample proportion of Yj and the posterior probability of protein
i could be inferred by the sample proportion of Xi or by the posterior sample mean
of Pr(WXi > 0).
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